Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes
Open Access
- 29 August 2019
- journal article
- research article
- Published by Springer Nature in EMBO Reports
- Vol. 20 (10) , e48155
Abstract
Epigenetic regulators are often hijacked by cancer cells to sustain malignant phenotypes. How cells repurpose key regulators of cell identity as tumour‐promoting factors is unclear. The antithetic role of the Polycomb component EZH2 in normal brain and glioma provides a paradigm to dissect how wild‐type chromatin modifiers gain a pathological function in cancer. Here, we show that oncogenic signalling induces redistribution of EZH2 across the genome, and through misregulation of homeotic genes corrupts the identity of neural cells. Characterisation of EZH2 targets in de novo transformed cells, combined with analysis of glioma patient datasets and cell lines, reveals that acquisition of tumorigenic potential is accompanied by a transcriptional switch involving de‐repression of spinal cord‐specifying HOX genes and concomitant silencing of the empty spiracles homologue EMX2 , a critical regulator of neurogenesis in the forebrain. Maintenance of tumorigenic potential by glioblastoma cells requires EMX2 repression, since forced EMX2 expression prevents tumour formation. Thus, by redistributing EZH2 across the genome, cancer cells subvert developmental transcriptional programmes that specify normal cell identity and remove physiological breaks that restrain cell proliferation.Keywords
Funding Information
- Cancer Research UK (FC001152)
- Medical Research Council (FC001152)
- Wellcome Trust (FC001152)
- National Institute for Health and Care Research
- Brain Tumour Research
This publication has 103 references indexed in Scilit:
- RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3Cell, 2012
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic TransformationCancer Cell, 2010
- NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 2010
- Molecular Maps of the Reorganization of Genome-Nuclear Lamina Interactions during DifferentiationMolecular Cell, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma MetastasisCell, 2009
- Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem CellsCell, 2009
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating CellsCancer Cell, 2008